This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. Ultragenyx uses adeno-associated virus 8 (AAV8) gene therapy to induce stable OTC geneexpression.
CHOP researchers find small changes in RNA due to RNA editing could have a large impact on geneexpression and phenotype Philadelphia, March 9, 2021–Combining computational mining of big data with experimental testing in the lab, researchers at Children’s Hospital of Philadelphia (CHOP) have identified RNA editing events that influence (..)
AOC 1020 has been designed for the treatment of the underlying cause of FSHD, which is caused by the abnormal expression of a gene known as double homeobox 4 or DUX4. Avidity Biosciences’ AOC 1020 is intended to reduce the DUX4 mRNA and DUX4 protein expression in muscles in these patients. .
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers identify key RNA “gatekeeper” in geneexpression, pointing to possible new drug targets.An
Administration routes for gene therapies can differ depending on the indication target’s delivery needs. For example, it is beneficial to administer RNA treatments for some lung diseases directly to the disease site through inhalation. GeneExpression Considerations. Route of Administration Considerations.
In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.
An international team of scientists from the University of Turku, Finland and PennState University, USA have solved a long-standing mystery of how living organisms distinguish RNA and DNA building blocks during geneexpression paving the way for the design of new antiviral drugs. All cellular […].
Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research Ocean Genomics Partners With Geninus to Co-Develop RNA-Based Biomarkers and Advance Research PITTSBURGH–(BUSINESS WIRE)–#RNA–Ocean Genomics (Pittsburgh, PA), a world leader in AI-based geneexpression analysis and RNA biomarker … Continue (..)
RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.
Capturing how RNA polymerase enzymes kick off transcription On scales too small for our eyes to see, the business of life happens through the making of proteins, which impart to our cells both structure and function.
Innovation S-curve for the pharmaceutical industry Transcription factors for genetically modified cells is a key innovation area in the pharmaceutical industry Transcription factors are proteins which control geneexpression by controlling the rate of transcription of genetic information from DNA to RNA.
Gümrükcü is a specialist in geneexpression profiling in stem cells, and has been working on ways to deliver stem cell transplants to treat cancer without the need for high-dose induction chemotherapy to destroy the patient’s bone marrow.
Scientists discover small RNA that regulates bacterial infection People with weakened immune systems are at constant risk of infection. Abell Chair in Molecular and Cellular Biology – and Pengbo Cao, a postdoctoral researcher in Whiteley’s lab, discovered a gene that drives the switch. aeruginosa infections.
The 2024 Nobel Prize in Physiology or Medicine has been awarded to American scientists Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNA (or miRNA) and its role in post-transcriptional gene regulation. A gene contains instructions within our DNA.
Another therapy by the same company named GTX-102 is also an antisense therapy; however, it silences geneexpression by binding to the RNA molecule that regulates its expression. It is designed to target and inhibit the molecule that silences the paternal copy of the gene, called UBE3A antisense transcript (UBE3A-AS).
These modifications regulate geneexpression without changing the sequence or structure of DNA. The CRISPR gene editing system consists of the Cas9 enzyme, which serves as molecular scissors to cleave double-stranded DNA, and a guide RNA template targeted to a specific genomic sequence, which allows for precise editing.
Join the Epigenetic Therapeutic Targets Summit – the only virtual summit dedicated to the clinical translation and optimization of therapeutic candidates targeting epigenetic mechanisms of geneexpression.
InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate geneexpression in cells.
Molecular diagnostic tests refer to tests intended to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease. This technology can identify genetic variations, mutations, and expression patterns associated with various health conditions. What are Molecular Diagnostic Tests?
These platforms — Bobcat mRNATM, controllable self-replicating RNA (c-srRNA) and ZSCAN4 delivered by an RNA virus — represent the forefront of genetic therapy, harnessing the power of mRNA to combat diseases at their genetic roots. The essence of the c-srRNA platform lies in its innovative use of temperature as a regulatory mechanism.
Mechanism of Gene Switch During the transcription process, the promoter region, which is located near the upstream end of each gene, binds to transcription factor, which is a specific type of protein. An additional level of genetic control is provided by gene switches that are located upstream of the promoter region.
The current study extends on that finding and provides crucial mechanistic and clinical insights into the beneficial effects of verapamil in Type 1 diabetes, using proteomics analysis and RNA sequencing.
Cas9 is the protein used in the gene editing process called CRISPR. Cas9 binds and uses RNA as an address-tag. The system allows scientists, by synthesizing a specific “address-tag” RNA, to bring Cas9 to a precise location in genome and therefore cut and splice genes at specific sites.
These modifications regulate geneexpression without altering the sequence or structure of DNA. The CRISPR gene editing system consists of the Cas9 enzyme, which serves as molecular scissors to cleave double-stranded DNA, and a guide RNA template targeted to a specific genomic sequence, which allows for precise editing.
Studies have identified the presence of two types of HIV-infected CD4+ T cells: ‘Transcriptionally inactive’ cells that do not typically produce viral RNA or viral proteins. Transcriptionally active’ cells in which HIV RNA is actively transcribed to make copies of the virus (despite long-term ART).
those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. greater safety, transient and reversible effect on geneexpression).
About STP705
Sirnaomics’ leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-?1 1 and COX-2 geneexpression.
For instance, GTX-102 , an antisense therapy silencing the geneexpression by binding to the RNA molecule behind the regulation of its expression, has also secured USFDA Fast Track Designation. Although, it can be relieving that other players turned to different approaches for finding a cure for Angelman syndrome.
BOSTON – An important player in the healthy development of female embryos turns out also to play a key role in regulating the behavior of chromosome loops and geneexpression in both sexes, according to a new study by researchers at Massachusetts General Hospital (MGH).
A female’s second X chromosome is typically silenced (so that females don’t get an overdose of X chromosome genes) through X-linked inactivation, a process where the chromosome is coated with an outer layer of non-coding RNA. One of these doubly active genes is KDM6A. KDM6A Variant.
Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. STP705 is a small interfering RNA (siRNA) therapy that leverages a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-beta1 and COX-2 geneexpression.
CTCs enable the complete picture of a cancer to be seen, as, being an intact cell, they allow DNA, RNA and protein analysis and thus provide comparable analysis to a tissue biopsy. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive).
The system induces silencing of the foreign genetic material through RNA interference that involves pairing of CRISPR RNAs (crRNAs) with trans-activating crRNA (tracrRNA) — the RNA duplex then directs the CRISPR-associated protein Cas9 to cleave target DNA. Single-Cell RNA Sequencing.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content